Clinical Trials Logo

Clinical Trial Summary

This prospective cohort study aims to establish prognostic models, to discover toxicity associated predictors and to validate randomized trials in clinical practice.

Clinical Trial Description


Study Design

Related Conditions & MeSH terms

NCT number NCT03003182
Study type Observational
Source Sun Yat-sen University
Contact Fang-Yun Xie, MD
Phone +86-02087342618
Email [email protected]
Status Recruiting
Phase N/A
Start date May 10, 2017
Completion date May 2021

See also
  Status Clinical Trial Phase
Active, not recruiting NCT00370890 - A Trial of Adjuvant Chemotherapy in Nasopharyngeal Carcinoma Patients With Residual Epstein-Barr Virus (EBV) DNA Following Radiotherapy Phase 3
Completed NCT00697619 - To Evaluate the Efficacy of ZOMETA® in Treatment of Bone Metastases in Patients With Stage IV Nasopharyngeal Cancer Phase 2
Completed NCT00078546 - EBV-Specific CTLs Following CD45 Antibody to Patients With Epstein-Barr Virus (EBV) + Nasopharyngeal Carcinoma (NPC) Phase 1
Recruiting NCT04453826 - Concurrent and Adjuvant PD1 Treatment Combined With Chemo-radiotherapy for High-risk Nasopharyngeal Carcinoma Phase 3
Active, not recruiting NCT01074021 - Nimotuzumab in Combination With Chemoradiation for Nasopharyngeal Cancer Phase 3
Active, not recruiting NCT03890185 - Docetaxal & Cisplatin vs LDFRT + Docetaxal & Cisplatin in Locally Advanced NPC Phase 2
Not yet recruiting NCT04158414 - Applying PET/MR in Oncology - a Prospective Project N/A
Recruiting NCT02012699 - Integrated Cancer Repository for Cancer Research
Completed NCT02608073 - A Study of Capecitabine (Xeloda) as First-Line Chemotherapy in Participants With Metastatic Nasopharyngeal Cancer Phase 2
Completed NCT03656250 - Assessment of Treatment Response of Nasopharyngeal Cancer Using Simultaneous 18F-FDG-PET and MRI
Recruiting NCT04476641 - A Study of DC-CIK Immunotherapy in the Treatment of Solid Tumors Phase 2
Terminated NCT03144661 - An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies Phase 1
Active, not recruiting NCT01094405 - Efficacy of Recombinant Epstein-Barr Virus (EBV) Vaccine in Patients With Nasopharyngeal Cancer Who Had Residual EBV DNA Load After Conventional Therapy Phase 2
Completed NCT01800071 - A Phase Ib Trial of MVA-EBNA1/LMP2 Vaccine in Nasopharyngeal Carcinoma Phase 1
Recruiting NCT00304694 - Whole-Body 18F-FDG PET in Induction Chemotherapeutic Response for Advanced NPC Patients N/A
Not yet recruiting NCT04875611 - Nivolumab in Nasopharyngeal Cancer With Progression During or After Platinum-based Treatment Phase 2
Completed NCT01379872 - Assessment of New Radiation Oncology Technologies and Treatments N/A
Recruiting NCT00941538 - Screening for Nasopharyngeal Carcinoma in High Risk Populations N/A
Completed NCT00603915 - A Study of Gemcitabine and Cisplatin/Carboplatin Plus Erlotinib in Patients With Nasopharyngeal Cancer Phase 2
Not yet recruiting NCT04004871 - Induction Chemotherapy With Nab-paclitaxel, Cisplatin and Fluorouracil for Locoregionally Advanced Nasopharyngeal Carcinoma Phase 2